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Myeloperoxidase (MPO) and C-reactive protein (CRP) 
may play critical roles in generation of oxidative stress 
and the development of the systemic inflammatory re-
sponse. The aim of the study was to determine the effect 
of atorvastatin therapy on the MPO gene expression and 
its plasma level in relation to lipids level lowering and 
an anti-inflammatory response in patients after acute 
myocardial infarction. The research material was repre-
sented by 112 samples. Thirty-eight patients with first 
AMI receiving atorvastatin therapy (40 mg/day) and fol-
lowed up for one month were involved in the study. The 
relative MPO gene expression in peripheral blood mono-
nuclear cells (PBMCs) was examined using RT-qPCR in 
38 patients before-, 38 patients after-therapy and in 36 
patients as the control group. The plasma concentrations 
of MPO and serum concentrations of biochemical param-
eters were determined using commercially available di-
agnostic tests. After one month of atorvastatin therapy, 
in 60.5% patients a decrease of MPO gene expression, 
whereas in 39.5% patients an increase, was observed. 
The plasma MPO levels behaved in the same way as the 
MPO gene expression. However, the serum lipids and 
CRP concentrations were significantly lower after one 
month of atorvastatin therapy in both groups of patients 
— with decreased and increased MPO gene expression. 
Atorvastatin exhibited a different effect on MPO gene 
expression and its plasma level. Short-term atorvastatin 
therapy resulted in lipid lowering and anti-inflammatory 
activity in patients after AMI, independently of its effect 
on MPO gene expression. The molecular mechanisms of 
this phenomenon are not yet defined and require further 
research.
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INTRODUCTION
Acute coronary syndrome (ACS) is a predominant 
cause of human morbidity and mortality in developed 
countries. Inflammatory processes play a major role in 
all stages of the evolution of atherosclerotic plaque, from 
the early development of endothelial dysfunction, to the 
formation of the mature atheroma and its subsequent 
rupture (Nicholls et al., 2005). Whereas the deposition 
and oxidation of lipids in atherosclerotic plaques are 
considered central events in plaque destabilization, main-
taining the capping of the plaque by the extracellular ma-
trix, plays a critical role in stabilizing the atherosclerotic 
lesions (Lau et al., 2006). Myeloperoxidase (MPO) — en-
zyme released from activated neutrophils and monocytes 
during inflammation — is involved in the promotion 
of atherosclerosis, the destabilization of atherosclerot-
ic plaque and the pathogenesis of ACS (Nicholls et al., 
2005; Tsimikas et al., 2006; Ndrepepa et al., 2011). MPO 
deposition has been shown in a murine model of acute 
myocardial infarction (AMI) to be increased near the 
sites of myocardial rupture (Vasilyev et al., 2005). MPO 
is one of the important elements in the generation of 
oxidative stress and the pro-inflammatory stage progress 
(Zhang et al., 2001). Systemic levels of MPO are signifi-
cantly increased in subjects with angiographically docu-
mented cardiovascular disease (CVD), while high circu-
lating MPO levels have been reported to be a risk factor 
for early adverse cardiovascular events in acute coronary 
syndromes (Andreou et al., 2010). Patients, who are de-
ficient in MPO, are less susceptible to CVD (Kumar et 
al., 2005). MPO has also been listed as a candidate and 
potential biomarker of coronary atherosclerosis to pre-
dict future adverse clinical outcomes in subjects with 
ACS (Apple et al., 2011). However, recent research has 
given conflicting results and the significance of MPO in 
the management of patients with coronary artery disease 
(CAD) is still disputable (Ndrepepa et al., 2011; Chevrier 
et al., 2006; Eggers et al., 2010).
Statins, inhibitors of HMG-CoA reductase, have 
pleiotropic benefits independent of cholesterol levels, 
including anti-oxidant and anti-inflammatory effects. Sta-
tin-treated patients have significantly lower risk of CVD 
and myocardial infarction than patients using other lip-
id lowering agents (LLA), despite comparable reduction 
in cholesterol (Pedersen, 2004). Retrospective epidemi-
ological studies found that patients treated with statins, 
but not other LLA, had reduced incidence of Alzhei-
mer’s disease (AD) or dementia. One feature common 
to CVD and AD is chronic inflammation with the in-
filtration of reactive monocyte/macrophages expressing 
MPO (Kumar et al., 2005). One of the possible mech-
anisms of statins’ action is their effect on MPO, which 
displays a diversity of the proatherogenic and pro-in-
*e-mail: gsygitowicz@poczta.onet.pl
Abbreviations: ACS, acute coronary syndrome; AD, Alzheimer’s 
disease; CRP, C-reactive protein; CVD, cardiovascular disease; LLA, 
lipid lowering agents; MPO, myeloperoxidase
Vol. 63, No 1/2016
89–95
http://dx.doi.org/10.18388/abp.2015_1014
90           2016G. Sygitowicz and others
flammatory properties including catalytic consumption 
of endothelium-derived nitric oxide, LDL oxidation, and 
functional inactivation of HDL (Boudjeltia et al., 2004, 
Nicholls et al., 2005). It has been established that treat-
ment with atorvastatin for only one week can reduce 
the serum concentration of MPO and hsCRP in patients 
with ACS (Zhou et al., 2006). Therefore, the aim of the 
present study was to determine the effect of atorvastatin 
therapy on the MPO gene expression in peripheral blood 
mononuclear cells (PBMCs) in relation to MPO plasma 
level. In addition, we explored the relationship between 
MPO gene expression and lipids level lowering and anti-
inflammatory action of atorvastatin in patients after on-
set of myocardial infarction who had indications for the 
initiation of statin therapy.
MATERIALS AND METHODS
Subjects and study population. Thirty-eight consec-
utive patients (27 males, average age 59 (53–65) years, 
hospitalized for AMI were enrolled to the study (the 
baseline demographic is presented in Table 1)). The con-
trol group included 36, apparently healthy people (aver-
age age 57 (51–60) years, 9 males).
In 27 patients enrolled in the study ST-segment ele-
vation MI (STEMI) was recognized. Eleven of the in-
vestigated patients underwent non ST-segment elevation 
MI (NSTEMI). All patients were referred to the cathe-
terization laboratory for primary percutaneous coronary 
angioplasty (PTCA).
The inclusion criteria were: first episode of AMI, no 
history of dyslipideamia before enrollment in the study 
and age > 18 years. Accordingly to the Third Universal 
Definition of Myocardial Infarction (The Writing Group 
et al., 2012) the diagnosis of MI was confirmed by the 
detection of cardiac necrosis blood markers (troponin I) 
and the presence of at least one of the following: symp-
toms of ischaemia, new significant ST-segment–T wave 
changes, new left bundle branch block (LBBB), the de-
velopment of pathological Q waves in the ECG or im-
aging evidence of a new loss of viable myocardium or 
new regional wall motion abnormalities. After echocar-
diographic assessment five cases of severe left ventricle 
dysfunction with LVEF < 35% were observed. All the 
patients investigated received standard antiplatelet ther-
apy (aspirin, clopidogrel). The GFR of each subject was 
estimated using the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) formula to assess the re-
nal function.
The exclusion criteria consisted of: prior lipid-lower-
ing therapy with statins and/or fibrates, history of any 
acute renal failure, hepatic failure, neoplasms, chronic 
inflammatory diseases, diabetes mellitus type 1, heredi-
tary hipercholesterolaemia and pregnancy. Blood samples 
were collected during the first 24 hours of hospitaliza-
tion in the Intensive Cardiological Care Unit before the 
first dose of statin. The patients fasted overnight and re-
frained from smoking for 12 hours. Thirty-eight patients 
with first AMI receiving atorvastatin therapy (40 mg per 
day) were followed up for a period of one month. All 
participants were fully informed of the aim of the study 
and formal consent was obtained from the patients be-
fore blood samples were collected. The presented trial 
complies with the ethical guidelines of the Declaration 
of Helsinki and the study protocol was approved by the 
local Ethical Committee.
Biochemical analyses. MPO was analyzed in sodium 
citrate plasma that had been stored frozen in aliquots at 
–20oC. MPO levels were measured using a chemilumi-
nescent microparticle immunoassay (CMIA technology) 
for the quantitative determination of myeloperoxidase 
on the ARCHITECT iSystem according to manufactur-
er’s protocol (Architect i2000 SR, Abbott Diagnostics, 
Abbott Park, IL). Serum lipoproteins (total cholesterol, 
triglycerides, and HDL cholesterol) and glucose levels, 
in samples that had been stored frozen in aliquost at 
–20oC, were determined by automated analyzer Cobas 
c501 (Roche Diagnostics GmBH, Mannheim, Germany). 
LDL cholesterol level was estimated by the Friedewald 
formula unless triglyceride levels were > 300 mg/dL, in 
which case direct LDL cholesterol level determination 
was performed. The concentrations of high sensitive 
C-reactive protein (hsCRP) were measured using flex® re-
agents cartridge and Dimension Xpand instrument (Sie-
mens HealthCare Diagnostics Ltd., Erlangen, Germany).
RNA isolation. Sodium citrate-blood was collected 
from patients at two time points: before and one month 
after atorvastatin treatment. Peripheral blood mono-
nuclear cells (PBMCs), mainly comprising monocytes, 
T cells, B cells and natural killer (NK) cells, were pu-
rified using a BD Vacutainer® CPT™ Cell Preparation 
Tubes in accordance with the manufacturer’s instructions 
(Becton, Dickinson and Co., Franklin Lakes, NJ, USA). 
Total RNA was isolated from PBMCs with the MagNA 
Pure Compact System (Roche Diagnostics GmbH, Ger-
many) following the manufacturer’s recommendations. 
The RNA quantity was determined by UV absorption 
(Nanodrop, LabTech International, UK). The quality of 
RNA samples was verified using Agilent 2100 Bioana-
lizer© and RNA 6000 Nano Kit (Agilent, Santa Clara, 
CA, USA). Samples with RNA integrity value of eight or 
above were considered suitable for analysis. RNA sam-
ples were stored at –80ºC until further analysis.
Quantitative real-time RT-qPCR. The real-
time reverse transcription-polymerase chain reaction 
(RT-qPCR) was used to quantify MPO gene expression 
levels. Reverse transcription was carried out using to-
tal RNA samples (200 ng) and the QuantiTect Reverse 
Transcription kit (Qiagen, Hilden Germany) according 
Table 1. Baseline demographic in studied patients.
Number of patients, n 38
*Median age 59 (53–65) yrs
Male gender, n (%) 27 (71.1%)
STEMI, n (%) 27 (71.5%)
NSTEMI, n (%) 11 (28.9%)
Hypertension, n (%) 19 (50%)
Diabetes mellitus, n (%) 5 (13,2%)
Prediabetes, n (%)
Impaired fasting glycaemia
Impaired glucose tolerance
12 (31.6%)
8 (21.1%) 
4 (10.5%)
Obesity **BMI >30, n (%) 8 (21.1%)
Overweight **BMI >25, n (%) 12 (31.6%)
Chronic Kidney Disease, n (%)
Stage 3 (***eGFR < 60 ml/min/1,73m2)
Stage 4 (***eGFR < 30 ml/min/1,73m2)
6 (15.8%)
5 (13.2%) 
1 (2.6%)
Smoking, n (%) 16 (42.1%)
Family history of cardiovascular dise-
ases, n (%) 4 (10.5%)
Data are presented as number (percentage) or *median (IQR, range 
from the 25th to the 75th percentile), **BMI, body mass index, ***eGFR, 
estimated glomerular filtration rate.
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to the manufacturer’s protocol. Primer sequences were 
as follow: MPO forward, 5’ CACTGGCGTCAACT-
GCGAGA 3’ and reverse 5’ TGCTGGCGTCCAC-
GAAGGAA 3’; TUBB forward, 5’ CTTCAAGCG-
CATCTCGGAGC 3’ and reverse 5’ TGCGGTG-
GCATCCTGGTACT 3’. The specificity of the ampli-
fied product was demonstrated by melting curve analy-
sis and agarose gel electrophoresis (data not shown). 
Each sample was run in triplicate in 96-well plates 
using LightCycler®480 and LightCycler®480 FastStart 
SYBR Green I Master (Roche Diagnostics GmbH, 
Germany). Quantification cycles (Cq) were calculated 
using the second derivative method (LightCycler®480 
Software, Version 1.5 provided by Roche). The fold 
change of gene expression levels, corrected for the effi-
ciency was analyzed using Relative Expression Software 
Tool (REST 2009) (Pfaffl et al., 2002). Tubulin, beta 
class I (TUBB) was used as a normalization (house-
keeping) gene since its expression did not significantly 
fluctuate between investigated groups in this study. All 
experiments (sample collection, preparation and stor-
age, primer design) were performed according to the 
MIQE guidelines (Bustin et al., 2009).
Statistical analysis. Statistical analysis was performed 
using the statistical software STATISTICA version 10 
and p values < 0.05 were considered as statistically sig-
nificant. Continuous variables were tested for normal 
distribution with the Shapiro-Wilk test. Results for nor-
mally distributed continuous variables are expressed as 
mean±standard deviation and mean values were com-
pared with unpaired Student’s t-test. Continuous vari-
ables with non-normal distribution are presented as the 
median value and the interquartile range (IQR, range 
from the 25th to the 75th percentile). Between-group 
comparisons of the distributions were assessed using the 
Wilcoxon rank-sum test. The correlation among continu-
ous variables was assessed with Spearman rank correla-
tion coefficient.
RESULTS
The median MPO plasma levels were significant-
ly higher in all studied patients before therapy in rela-
tion the control group (152.5 (109.5–240.5) pmol/L vs 
100.8 (82.1–125.2) pmol/L; p = 0.0004, respectively) 
(Fig. 1B). Likewise, the median MPO plasma levels were 
Figure 1. (A) MPO gene expression in PBMCs and (B) plasma MPO level in the control group versus studied patients (before and af-
ter atorvastatin therapy).
(A) mRNA expression levels for MPO gene were determined by RT-qPCR and normalized to reference gene TUBB. Data are presented as 
fold change relative to the expression in the control group±standard error. (B) Box-whisker plots of the MPO level before and after ator-
vastatin treatment are shown. Boxes encompass the 25th (Q1) to 75th (Q3) quartiles, the whiskers represent the 10–90% range of obser-
vations. Points within boxes represent median values.
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also significantly higher in all studied patients after the 
treatment in comparison with the healthy group (165.9 
(104.5–220.5) pmol/L vs 100.8 (82.1–125.2) pmol/L; 
p = 0.0011, respectively) (Fig. 1B).
The MPO gene expression was significantly higher in 
all studied patients both before and after atorvastatin 
therapy in comparison to the control group (fold change 
1.711; p = 0.0001 and fold change 1.461; p = 0.001, re-
spectively) (Fig. 1A). In all studied patients a moderate 
correlation between the changes of plasma MPO levels 
(changes between the values after and before the thera-
py) and relative MPO gene expression (r = 0.476; p < 0.05) 
was observed.
The above mentioned results particularly proved 
that there is no relationship between MPO gene ex-
pression and its level in the plasma, which was sur-
prising and probably caused by the ontogenetic vari-
ability of atorvastatin therapy response. Therefore, we 
distinguished two patient subgroups: with the decrease 
and the increase in MPO gene expression. The gene 
expression analysis revealed decreased MPO gene ex-
pression in 23 patients (60.5%) and increased MPO 
gene expression in 15 patients (39.5%) (Fig. 2A). Af-
ter one month of atorvastatin therapy in patients with 
down-regulated MPO gene expression (n=23) (fold 
change –1.845; p = 0.005) (Fig. 2A) a significant re-
duction in MPO plasma levels (189.9 (128.6–378.7) 
pmol/L vs 176.0 (95.7–224.5) pmol/L; p = 0.0447) 
(Fig. 2B) was achieved. In contrast, in the subgroup 
of patients with up-regulation of the MPO gene ex-
pression observed (n=15) (fold change 1.545; p>0.05) 
(Fig. 2A) the median MPO plasma level was also sig-
nificantly higher after one month of atorvastatin ther-
apy: 121.8 (88.1–165.0) pmol/L vs 139.0 (114.1–220.5) 
pmol/L; p = 0.0309) (Fig. 2B).
The lipid lowering effect of atorvastatin therapy is 
presented in Table 2. The decrease of total cholesterol 
and LDL cholesterol concentration was almost the 
same in both groups — with decreased and increased 
MPO gene expression, which may suggest that the li-
pid lowering and anti-inflammatory effect of atorvas-
tatin is independent from its influence on MPO gene 
expression.
The median hsCRP serum levels were significant-
ly higher in all studied patients (n=38) before thera-
py versus the healthy group (n=36) (12.3 (5.8–23.4) 
Figure 2. (A) MPO gene expression in PBMCs and (B) plasma MPO level before and after atorvastatin therapy in population with de-
creased- and with increased MPO gene expression.
(A) mRNA expression levels for MPO gene were determined by RT-qPCR and normalized to reference gene TUBB. Data are presented as 
fold change relative to expression in the group before therapy±standard error. p=0.005, after versus before atorvastatin therapy. (B) Box-
whisker plots of MPO level before and after are shown. Boxes encompass the 25th (Q1) to 75th (Q3) quartiles, the whiskers represent the 
10–90% range of observations. Points within boxes represent median values.
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mg/L vs 1.29 (0.98–2.00) mg/L; p<0.0001). More-
over, the median hsCRP serum levels measured one 
month after atorvastatin treatment were still signifi-
cantly higher in studied patients in comparison to the 
control group (2.1 (1.4–6.3) mg/L vs 1.29 (0.98–2.00) 
mg/L; p = 0.0268).
It is noteworthy that one month atorvastatin treat-
ment resulted in the same effect on the hsCRP concen-
trations independently of the effect on the MPO gene 
expressions. In the group of patients with decreased 
MPO gene expressions, hsCRP levels were decreased: 
12.9 (6.8–36.2) mg/L vs 1.9 (1.34–5.1) mg/L; p < 0.0001 
and in the group of patients with increased MPO gene 
expressions the hsCRP levels also decreased: 10.2 (1.94–
18.8) mg/L vs 2.8 (1.52–7.24) mg/L; p = 0.006 (Table 2).
In all studied patients a weak correlation between 
changes of serum hsCRP levels (changes between after 
and before the therapy) and relative MPO gene expres-
sion (r = 0.365; p < 0.05) was observed. In addition, statis-
tical analysis demonstrated that there is a strong correla-
tion between changes of serum hsCRP levels and chang-
es of plasma MPO levels in studied patients (r = 0.632; 
p < 0.05) (Fig. 3).
DISCUSSION
There is increasing evidence to sug-
gest that the benefits of statins are not 
limited to the effect on serum choles-
terol (Davignon, 2004). The cholesterol 
independent effects of statins include 
the decrease in oxidative stress and 
inflammation (Pedersen, 2004; Green-
wood et al., 2007; Wang et al., 2008). 
Peripheral blood mononuclear cells 
(PBMCs) play a key role in the ex-
pansion of inflammation and oxidative 
stress (Zhang et al., 2001). We decided 
to use PBMCs to conduct the study 
because they can be obtained relatively 
easily from routinely collected blood 
samples, and represent the only site 
of active gene expression in blood. 
The PBMCs mainly comprise mono-
cytes, T cells, B cells, and natural killer 
(NK) cells. The PBMCs contain dif-
ferent cell types that play important 
roles in the immune system monitoring 
and respond in an inflammatory man-
ner. MPO is abundantly expressed not 
only in the granules of most leukocyte 
subspecies, including neutrophils, but also in monocytes 
(PBMCs population). MPO increases the oxidative po-
tential of hydrogen peroxide by generating hydrochlor-
ous acid through the peroxidation of chloride (Byun et 
al., 1999). MPO is involved in low-density lipoprotein 
(LDL) oxidation, high density lipoprotein (HDL) mod-
ification leading to its functional impairment, nitric ox-
ide breakdown, endothelial dysfunction and in post-MI 
remodeling. The role of MPO, particularly in the gen-
eration of dysfunctional HDL particles, seems to be 
important as the heart ischemia and its consequences 
can occur even in the presence of high levels of HDL 
cholesterol. Taken together all these data, it is of a great 
importance to reveal what is the effect of lipid lowering 
atorvastatin therapy, not only in the context of the HDL 
and LDL cholesterol concentration but also on the MPO 
gene expression as well as on the systemic level and/or 
on enzyme activity in patients undergoing the therapy.
Before the statin therapy (2–3 days after the onset of 
AMI), the MPO gene expression in PBMCs was signifi-
cantly higher in patients than in control individuals with 
proven coronary artery disease (Fig. 1A). It has been 
Table 2. Lipid-lowering capabilities and anti-inflammatory action of atorvastatin therapy.
Parameter
Decreased MPO gene expression (n=23) Increased MPO gene expression (n=15)
Before therapy
(n=23)
After therapy
(n=23) Δ p-value
Before therapy
(n=15)
After therapy
(n=15) Δ p-value
Total cholesterol 
[mmol/L]* 4.86 ± 1.04 3.39 ± 0.73 ↓ 30.2% p<0.0001 4.91 ± 0.75 3.33 ± 0.56 ↓ 32.2% p<0.0001
LDL-cholesterol  
[mmol/L]* 3.22 ± 1.13 2.08 ± 0.48 ↓ 35.4% p<0.0002 3.15 ± 0.68 2.07 ± 0.44 ↓ 34.3% p<0.0001
HDL-cholesterol  
[mmol/L]* 1.10 ± 0.32 1.11 ± 0.30 ↑ 0.91% p=0.969 1.25 ± 0.29 1.21 ± 0.27 ↓ 3.2% p=0.563
Triglicerides  
[mmol/L]* 1.61 ± 1.14 1.40 ± 0.85 ↓ 13.0% p=0.455 1.36 ± 0.66 1.08 ± 0.34 ↓ 20.6% p=0.127
hsCRP
[mg/L]** 12.9 (6.8-36.2) 1.9 (1.34-5.1) ↓ 85.3% p<0.0001 10.2 (1.94-18.8) 2.8 (1.52-7.24) ↓ 72.5% p=0.006
Results are expressed as: *mean ± standard deviation; **median (25–75 percentiles); Δ, means difference in the concentration between before and 
after atorvastatin therapy.
Figure 3. Correlation between the changes of serum hsCRP concentrations and 
changes of plasma MPO levels in all studied patients.
Spearman’s rank strong correlation r = 0.632, p < 0.05.
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shown by Goldman et al. that MPO plasma levels re-
mained elevated until 4h after the onset of symptoms 
and declined thereafter. After 24hours however, MPO 
levels increased again (Goldmann et al., 2009). It has 
been indicated by Aminian et al. that coronary stenting 
is also associated with an acute and transient increase 
in plasma MPO levels in patients with stable angina but 
not in patients with acute myocardial infarction (Aminian 
et al., 2009). Given these observations and our results, 
it may be suggested that PBMCs are still activated after 
successful coronary intervention in patients with AMI.
In the present study, we showed for the first time 
that atorvastatin caused a different effect on the MPO 
gene expression. Individual responsiveness to atorvas-
tatin therapy is not uniform in all patients. After one 
month of atorvastatin therapy we observed a subgroup 
of patients (n=23) with significantly (p = 0.005) decreased 
MPO gene expression as well as the enzyme concentra-
tion in the circulation (Fig. 2A and Fig. 2B). It is inter-
esting that we were able to demonstrate numerous cases 
(15 patients) in which MPO gene expression (Fig. 2A) 
and plasma enzyme levels (Fig. 2B) were increased af-
ter one month therapy with atorvastatin. The different 
effect of atorvastatin therapy was independent from the 
anti-inflammatory action. In all studied patients signifi-
cant decrease in serum concentration of hsCRP was stat-
ed (Table 2). It may therefore be suggested that inflam-
matory mediators are not co-responsible for MPO gene 
expression in PBMCs. In addition, we did not observe 
any differences between both groups in the cholester-
ol-lowering activity of atorvastatin (Table 2).
The different effect of atorvastatin is very important, 
as well as the unexpected observation that several studies 
have consistently demonstrated that statins down-regu-
late MPO gene expression and reduce serum MPO con-
centration (Kumar et al., 2005; Zhou et al., 2006). The 
molecular mechanism of ontogenetic variability of ator-
vastatin treatment remains unclear. One of the possible 
explanations of the mechanism of a different effect of 
atorvastatin on MPO are the differences in its affinity 
to the active site of HMG-CoA reductase. Andreou et 
al. suggested that the inhibiting effects of rosuvastatin 
on MPO gene expression are probably class effects for 
these agents and are based on the inhibition of meva-
lonate-dependent isoprenylation of small GPT-binding 
proteins (Andreou et al., 2010). Rosuvastatin, howev-
er, has exhibited a more potent affinity for HMG-CoA 
reductase than other statins including atorvastatin (Ols-
son, 2001). Another possible mechanism responsible for 
this phenomenon is polymorphism in the promoter re-
gion of the MPO gene. Several genetic polymorphisms 
in the MPO gene were described (Wainstein et al., 2010; 
Scharnagi et al., 2014; Nikpoor et al., 2001). Some studies 
suggest that MPO polymorphism in the promoter region 
(–463G/A) might be associated with coronary artery dis-
ease (Castellani et al., 2006; Reynolds et al., 2006; Yang et 
al., 2013). However, this preliminary hypothesis still re-
quires detailed studies. In the present study, a statistically 
moderate correlation was observed between MPO gene 
expression and changes of MPO plasma level (r = 0.476; 
p < 0.05). Thus, the determination of MPO mRNA ex-
pression by RT-qPCR reflects the changes of MPO plas-
ma concentration, which should in turn allow the pre-
diction of the patient`s reaction to the atorvastatin treat-
ment. To our knowledge, little is known about the corre-
lation between MPO gene expression in PBMCs and the 
changes of plasma MPO concentration in patients soon 
after the onset of AMI treated with atorvastatin. Our 
results seem to suggest that monitoring of MPO gene 
expression during statin therapy is predictive for cardio-
vascular outcomes. These data raise the possibility that 
the evaluation of MPO gene expression using RT-qPCR 
may serve as a very useful tool for studying the molecu-
lar mechanisms of pleiotropic atorvastatin action.
A limitation of the present study is the small number 
of participants. In addition, we did not analyze differ-
ent doses of atorvastatin. We investigated only one typi-
cal dose of atorvastatin used for patients in secondary 
prevention after AMI. Our study did not show that the 
observed effects on MPO gene expression and MPO lev-
els are dose-dependent. Recently it has been stated that 
different statins produce highly different changes in gene 
expression (Leszczynska et al, 2011). Therefore, our ob-
servations are limited only to atorvastatin. Further stud-
ies with a larger number of patients are needed to con-
firm our results and their clinical significance.
CONCLUSIONS
The one month atorvastatin treatment of studied pa-
tients exhibited a different effect on the MPO gene ex-
pression and on the MPO plasma level. Not in all pa-
tients does atorvastatin inhibit MPO gene expression. 
There is a small group of patients with increased MPO 
gene expression. Lipids level lowering as well as anti-in-
flammatory activity of atorvastatin is independent of the 
effect on MPO gene expression. It may be assumed that 
the determination of MPO gene expression and/or MPO 
plasma concentration may be a useful adjunct to the as-
sessment of future cardiovascular events and of the po-
tential benefit from atorvastatin therapy.
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